Analytical Data
-
基因名
Staphylokinase
-
简介
Staphylokinase Protein efficiently converts plasminogen into active plasmin, a key enzyme in fibrinolysis. It forms a 1:1 complex with plasmin, activating additional plasminogen molecules and amplifying the fibrinolytic cascade. Staphylokinase Protein, S. aureus is the recombinant Staphylococcus aureus-derived Staphylokinase protein, expressed by E. coli , with tag free.
- Application
-
别名
Staphylokinase; Neutral proteinase; Protease III; SakSTAR; sak
-
种属
Staphylococcus aureus
-
表达系统
E. coli
-
标签
Tag Free
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P68802
-
表达区间
S28-K163
-
蛋白长度
Full Length of Mature Protein
-
分子量
15.6 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Staphylokinase (SAK) is a secreted protein produced by Staphylococcus aureus, known for its ability to activate plasminogen, converting it into plasmin, which subsequently leads to fibrinolysis. This characteristic positions SAK as a potential therapeutic agent for treating thrombotic disorders. The recombinant production of SAK has gained significant attention due to the increasing prevalence of antibiotic-resistant Staphylococcus aureus strains, necessitating alternative approaches for treatment. By employing recombinant DNA technology, researchers have successfully expressed SAK in various host systems, enhancing its yield and facilitating its purification for therapeutic use. Furthermore, studies have investigated the structure-function relationship of SAK, revealing insights into its mechanism of action and potential modifications to improve its efficacy and stability as a drug candidate. Overall, the exploration of recombinant Staphylokinase not only highlights the innovative applications of biotechnology in medicine but also underscores the need for continued research into effective treatments for cardiovascular diseases and other conditions associated with abnormal clot formation.
